fundsforNGOs

Joint Call for Proposals: Precision Biotherapeutics-mRNA Therapeutics for Fostering High Performance Biomanufacturing under BioE3 Policy (India)

#image_title

Deadline: 15-May-25

DBT and BIRAC invites proposals on ‘Precision Biotherapeutics-mRNA therapeutics ‘under the Bio E3 policy to further the indigenous development and manufacturing of this important biotherapeutic.

Precision Biotherapeutics- mRNA Therapeutics has been identified as one of the thematic sectors under the BioE3 Policy for ‘fostering high-performance biomanufacturing’.

mRNA therapy can potentially transform existing therapies or target difficult indications, including respiratory, cardiac, metabolic and autoimmune diseases, as well as cancer. mRNA technology can be used for the following therapeutic applications:

There are many benefits of mRNA therapies as compared to similar emerging platforms, such as modular nature with easy to-switch sequences for specifically targeting different proteins or genes, the potential to directly affect the underlying cause of a disease faster manufacturing times compared to antibodies or protein-based drugs, predictable pharmacokinetics, and lack of genome integration.

Categories
Eligibility Criteria

For more information, visit BIRAC.

Exit mobile version